TIDMDVRG
Deepverge PLC
10 February 2021
10 February 2021
DeepVerge PLC
("DeepVerge" or "the Company")
DeepVerge expands and adds two virus containment
laboratories
Additional laboratory space added for Skin Trust Club in
response to a 95% conversion rate in pre-registration for
personalised skincare Home Test Kit in the first 10 days
DeepVerge (LSE:DVRG.L), the environmental and life science AI
company, announces the addition of two Containment Level 3 (CL3)
laboratories at the Company's York, UK HQ facilities, creating a
Centre of Excellence for the EcowaterOS consortium, Labskin
initiatives, and increases laboratory space in preparation for the
launch of the Skin Trust Club, later this quarter.
The Centre of Excellence expands on the successful product
testing using Labskin with the SARS-CoV-2 virus with University of
Aberdeen, Public Health England, University of Liverpool, Cork
Institute of Technology and the work completed with industry
partners including Dell Technologies, Unilever and the Water Rising
Institute.
The CL3 laboratories will be focused on three areas:
1. Labskin is a key partner with the Liverpool Tropical School
of Medicine and Unilever in a multi-year project, the Strength in
Places partnership initiative, to create specialist, commercially
sustainable research platforms for infectious disease therapeutics
in north-west England. The project will see an expansion of Labskin
COVID-19 related services to provide clients with the ability to
test their soaps, washes and sanitisers and their effectiveness
against COVID-19 and other infectious diseases.
2. Further development alongside partners, such as the Aptamer
Group, Tyndall Foundries and a number of undisclosed partners to
investigate new variants of SARS-CoV-2 by adding a multiplex
nano-chip to test for a range of infectious viruses and bacteria on
a single chip for the MicrotoxPD range of equipment for detection
and identification of SARS-CoV-2, E.coli, Legionella and
Cryptosporidium.
3. Continued In-house development of the PulMoBioMed
breathalyser condensate on the identification of a variety of
respiratory diseases from influenza to SARS-CoV-2, as well as
delivering a diagnostic fingerprint for biomarkers relating to
diseases where there are no specific and sensitive diagnostic
methods available and prognosis is difficult. Further details on
this will be provided at a later date.
Retrofitting has begun with Modern Water equipment to add to the
range of real-time surveillance services in Water Monitoring. New
services for Modern Water clients will include standard tests
associated with dangerous pathogens, including contagious
infections as well as community detection of opioids. Future
services will include real-time monitoring and identification of
small and large molecules within the pharmaceutical sector during
bio-processing.
Gerard Brandon, CEO of DeepVerge, commented:
" The Centre of Excellence and the addition of two CL3
laboratories, at our York, UK headquarters is the culmination of
the successful outcome of handling with SARS-CoV-2 at the
University of Aberdeen and the University of Liverpool and used to
test dangerous viruses such as Ebola and Lassa as far back as 2015.
With Labskin services filling our existing space the 95% conversion
rate of pre-registration of the Skin Trust Club is a major
achievement and additional space is to be added to accommodate the
demand for home test kits which will roll out in March. "
For further information please contact:
+44 (0) 7340 055
DeepVerge plc Gerard Brandon, CEO 648
SPARK Advisory Partners Limited Neil Baldwin/Andrew +44 (0) 113 370
(Nominated Adviser) Emmott 8974
Turner Pope Investments (TPI) +44 (0) 20 3657
Limited (Broker) Andy Thacker/Zoe Alexander 0050
About DeepVerge plc (www.deepverge.com)
DeepVerge is an environmental and life science group of
companies that develops and applies AI and IoT technology to
analytical instruments for the analysis and identification of
bacteria, virus and toxins. Utilising artificial intelligent data
analytics to scientifically prove the impact of skincare product
claims on skin microbiome for most of the top 20 global cosmetic
company clients and remotely detect and identify in real-time,
dangerous pathogens in wastewater treatment plants, drinking water,
rivers, lakes and reservoirs.
Skin Trust Club (www.skintrustclub.com)
Note: There is limited availability on pre-registration of Skin
Trust Club. Priority will be given to pre-registered users for home
test kits at the formal launch. Pre-registration and the
downloadable App are free.
Customised skincare routine derived from a home test kit, lab
tested and linked to local environment via a free smartphone App
that updates in real-time and identifies ingredients that suit the
subscribers unique skin microbiome. This revolutionises how you
take care of your skin with your own skincare routine.
Home Test Kit comprises a single swab that maps the skin
microbiome delivering a report that produces the most appropriate
daily skincare routine based on science, not guesswork. Using
real-time air pollution and weather data from the customer's
location, the Skin Trust App builds a complete picture of the skin
microbiome and the impact of local surroundings.
Skin Trust Analysis includes:
-- Microbiome identification and quantification of living
organisms (bacteria, viruses, bacteriophages, fungi, parasites,
etc.) on the skin;
-- Skin gene expression analysis to quantify the biological
activity of living organisms on the skin ;
-- Analysis of metabolites in the skin sample;
-- Personal genetic analysis - analyse genomic data to
understand potential skin concerns and future risks but does not
analyse genes to identify inherited diseases.
Labskin (Life Science Division)
Labskin have been pioneering the development of a laboratory
grown human skin platform for more than 13 years and is the only
commercially available lab-grown full thickness human skin model
that naturally mimic the skin's microbiome. With top 20 global
consumer health and skincare clients, thousands of industry tests,
the good and bad bacteria that naturally exists on human skin is
present on Labskin when testing skin care, cosmetics, health care,
drug delivery or wound care products. The Labskin test platform and
protocols help clients maintain an optimum real-world environment,
when testing their new ingredients and existing products, that
shows the positive or negative impact on skin's natural
microflora.
Modern Water (Environmental Health Division)
Modern Water is a pioneering and innovative technology
subsidiary, and over a 30 year period, with installations in more
than 60 countries, this division has built core expertise in the
development of analytical instruments and technology for monitoring
toxicity in water, soil, food and industry. The core systems use
bioluminescent bacteria to perform biosensor testing that detects
the presence of toxic substances.
About Reach announcements
Reach is an investor communication service aimed at assisting
listed and unlisted (including AIM quoted) companies to distribute
media only / non-regulatory news releases such as marketing
messages, corporate and product information into the public domain.
An RNS Regulatory announcement is required to be notified under the
AIM Rules for Companies.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRADKCBPABKDCBK
(END) Dow Jones Newswires
February 10, 2021 02:00 ET (07:00 GMT)
Integumen (LSE:SKIN)
Historical Stock Chart
From Apr 2024 to May 2024
Integumen (LSE:SKIN)
Historical Stock Chart
From May 2023 to May 2024